Octagon Capital Advisors
Latest statistics and disclosures from Octagon Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVB.WS, APLS, DNTH, AVBP, CNTA, and represent 39.39% of Octagon Capital Advisors's stock portfolio.
- Added to shares of these 10 stocks: NUVB.WS (+$48M), TRVI (+$21M), TRML (+$14M), MLTX (+$12M), VSTM (+$10M), ATYR (+$8.0M), SPRY (+$7.9M), ABVX (+$7.7M), Maze Therapeatics (+$5.2M), DNTH.
- Started 8 new stock positions in TRML, MLTX, TRVI, VSTM, Maze Therapeatics, ABVX, Kalaris Therapeutics, SPRY.
- Reduced shares in these 10 stocks: INSM (-$40M), VRNA (-$23M), APLS (-$20M), DYN (-$16M), BBIO (-$12M), VRDN (-$5.7M), SRRK (-$5.1M), Allovir, NUVB, CNTA.
- Sold out of its positions in Allovir, BBIO, DYN, INSM, MRSN.
- Octagon Capital Advisors was a net buyer of stock by $9.3M.
- Octagon Capital Advisors has $517M in assets under management (AUM), dropping by -14.96%.
- Central Index Key (CIK): 0001839435
Tip: Access up to 7 years of quarterly data
Positions held by Octagon Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 34 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvation Bio *w Exp 02/10/202 (NUVB.WS) | 9.3 | $48M | +8650% | 27M | 1.76 |
|
| Apellis Pharmaceuticals (APLS) | 8.9 | $46M | -30% | 2.1M | 21.87 |
|
| Dianthus Therapeutics (DNTH) | 8.2 | $43M | +10% | 2.3M | 18.14 |
|
| Arrivent Biopharma (AVBP) | 7.4 | $38M | 2.1M | 18.49 |
|
|
| Centessa Pharmaceuticals Sponsored Ads Put Option (CNTA) | 5.6 | $29M | -5% | 2.0M | 14.38 |
|
| Trevi Therapeutics (TRVI) | 4.0 | $21M | NEW | 3.3M | 6.29 |
|
| Gossamer Bio (GOSS) | 3.9 | $20M | 18M | 1.10 |
|
|
| Ocular Therapeutix (OCUL) | 3.4 | $18M | 2.4M | 7.33 |
|
|
| Mind Medicine Mindmed Com New (MNMD) | 3.4 | $18M | 3.0M | 5.85 |
|
|
| Cogent Biosciences (COGT) | 3.2 | $17M | 2.8M | 5.99 |
|
|
| Kalvista Pharmaceuticals (KALV) | 3.1 | $16M | 1.4M | 11.54 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 2.9 | $15M | +2% | 11M | 1.39 |
|
| Nuvation Bio Com Cl A (NUVB) | 2.7 | $14M | -14% | 7.9M | 1.76 |
|
| Verona Pharma Sponsored Ads (VRNA) | 2.7 | $14M | -61% | 217k | 63.49 |
|
| Tourmaline Bio (TRML) | 2.7 | $14M | NEW | 905k | 15.21 |
|
| Merus N V (MRUS) | 2.5 | $13M | 308k | 42.09 |
|
|
| Pharvaris N V (PHVS) | 2.3 | $12M | 770k | 15.70 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 2.2 | $12M | NEW | 296k | 39.07 |
|
| Syndax Pharmaceuticals (SNDX) | 2.1 | $11M | 904k | 12.29 |
|
|
| Atyr Pharma Com New (ATYR) | 2.1 | $11M | +294% | 3.6M | 3.02 |
|
| Scholar Rock Hldg Corp (SRRK) | 2.0 | $11M | -32% | 329k | 32.15 |
|
| Verastem Com New (VSTM) | 2.0 | $10M | NEW | 1.7M | 6.03 |
|
| Regulus Therapeutics (RGLS) | 1.6 | $8.1M | -4% | 4.6M | 1.75 |
|
| Silverback Therapeutics (SPRY) | 1.5 | $7.9M | NEW | 625k | 12.58 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.5 | $7.7M | NEW | 1.2M | 6.25 |
|
| Erasca (ERAS) | 1.4 | $7.0M | 5.1M | 1.37 |
|
|
| Miragen Therapeutics (VRDN) | 1.2 | $6.1M | -48% | 450k | 13.48 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.1 | $5.9M | 1.1M | 5.31 |
|
|
| Unicycive Therapeutics (UNCY) | 1.1 | $5.7M | 10M | 0.57 |
|
|
| Maze Therapeatics | 1.0 | $5.2M | NEW | 468k | 11.01 |
|
| Perspective Therapeutics Com New (CATX) | 0.9 | $4.8M | -2% | 2.3M | 2.13 |
|
| Kalaris Therapeutics | 0.7 | $3.9M | NEW | 481k | 8.03 |
|
| Neurogene (NGNE) | 0.7 | $3.5M | 303k | 11.71 |
|
|
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.5 | $2.8M | 250k | 11.30 |
|
Past Filings by Octagon Capital Advisors
SEC 13F filings are viewable for Octagon Capital Advisors going back to 2020
- Octagon Capital Advisors 2025 Q1 restated filed May 16, 2025
- Octagon Capital Advisors 2025 Q1 filed May 15, 2025
- Octagon Capital Advisors 2024 Q4 filed Feb. 14, 2025
- Octagon Capital Advisors 2024 Q3 filed Nov. 14, 2024
- Octagon Capital Advisors 2024 Q2 filed Aug. 14, 2024
- Octagon Capital Advisors 2024 Q1 filed May 15, 2024
- Octagon Capital Advisors 2023 Q4 filed Feb. 14, 2024
- Octagon Capital Advisors 2023 Q3 filed Nov. 14, 2023
- Octagon Capital Advisors 2023 Q2 filed Aug. 14, 2023
- Octagon Capital Advisors 2023 Q1 filed May 15, 2023
- Octagon Capital Advisors 2022 Q4 filed Feb. 14, 2023
- Octagon Capital Advisors 2022 Q3 filed Nov. 14, 2022
- Octagon Capital Advisors 2022 Q2 filed Aug. 15, 2022
- Octagon Capital Advisors 2022 Q1 filed May 16, 2022
- Octagon Capital Advisors 2021 Q4 filed Feb. 14, 2022
- Octagon Capital Advisors 2021 Q3 filed Nov. 15, 2021